150 related articles for article (PubMed ID: 8913841)
21. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Aamdal S; Wolff I; Kaplan S; Paridaens R; Kerger J; Schachter J; Wanders J; Franklin HR; Verweij J
Eur J Cancer; 1994; 30A(8):1061-4. PubMed ID: 7654429
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
Bruntsch U; Heinrich B; Kaye SB; de Mulder PH; van Oosterom A; Paridaens R; Vermorken JB; Wanders J; Franklin H; Bayssas M
Eur J Cancer; 1994; 30A(8):1064-7. PubMed ID: 7654430
[TBL] [Abstract][Full Text] [Related]
25. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
[TBL] [Abstract][Full Text] [Related]
26. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Fossella FV; Lee JS; Berille J; Hong WK
Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
[TBL] [Abstract][Full Text] [Related]
27. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
29. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Kudelka AP; Verschraegen CF; Levy T; Edwards CL; Fishman A; Freedman RS; Kaplan A; Kieback DG; Mante R; Ende K; Steger M; Kavanagh JJ
Anticancer Drugs; 1996 Jun; 7(4):398-401. PubMed ID: 8826607
[TBL] [Abstract][Full Text] [Related]
30. [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Inuyama Y; Kataura A; Togawa K; Saijo S; Satake B; Takeoda S; Konno A; Ebihara S; Sasaki Y; Kida A; Kanzaki J; Ichikawa G; Kono N; Moriyama H; Kamata S; Miyake H; Sakai M; Horiuchi M; Kubota A; Tsukuda M; Matsuura H; Baba S; Saito H; Matsunaga T; Taguchi T
Gan To Kagaku Ryoho; 1999 Jan; 26(1):107-16. PubMed ID: 9987506
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Miller VA; Rigas JR; Francis PA; Grant SC; Pisters KM; Venkatraman ES; Woolley K; Heelan RT; Kris MG
Cancer; 1995 Feb; 75(4):968-72. PubMed ID: 7842417
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma.
Clark TB; Kemeny NE; Conti JA; Huang Y; Andre AM; Stockman J
Cancer Invest; 1998; 16(5):314-8. PubMed ID: 9627678
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG).
Cerny T; Kaplan S; Pavlidis N; Schöffski P; Epelbaum R; van Meerbeek J; Wanders J; Franklin HR; Kaye S
Br J Cancer; 1994 Aug; 70(2):384-7. PubMed ID: 7914429
[TBL] [Abstract][Full Text] [Related]
35. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of docetaxel in advanced soft tissue sarcomas.
Edmonson JH; Ebbert LP; Nascimento AG; Jung SH; McGaw H; Gerstner JB
Am J Clin Oncol; 1996 Dec; 19(6):574-6. PubMed ID: 8931674
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Rougier P
Anticancer Drugs; 1995 Jul; 6 Suppl 4():25-9. PubMed ID: 8745351
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
